U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06974812) titled 'IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors' on April 23.
Brief Summary: This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
Study Start Date: April 18
Study Type: INTERVENTIONAL
Condition:
Unresectable Locally Advanced or Metastatic Solid Tumors
Intervention:
DRUG: IBI3014
12 mg/kg D1 IV Q3W
DRUG: IBI3014
6 mg/kg D1 IV Q3W
DRUG: IBI3014
1 mg/kg D1 IV Q3W
DRUG: IBI3014
15 mg/kg D1 IV Q3W
DRUG: IBI3014
9 mg/kg D1 IV Q3W
DRUG: IBI3014
3 mg/kg D1 IV Q3W
Recrui...